NCT04899518 (OASIS-1) is a Phase 2, PHASE3 clinical trial of ALY688 Ophthalmic Solution in Dry Eye, sponsored by Allysta Pharmaceutical.

Who is sponsoring NCT04899518?

NCT04899518 is sponsored by Allysta Pharmaceutical.

What drugs are being tested in NCT04899518?

Interventions in NCT04899518: ALY688 Ophthalmic Solution.

Is NCT04899518 still recruiting?

NCT04899518 is currently completed. Last updated 16 March 2023.

Last reviewed 2023-03-16 · How we verify

NCT04899518: OASIS-1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease

Completed Phase 2, PHASE3 Last updated 16 March 2023

What this trial tests

Phase 2, PHASE3 trial testing ALY688 Ophthalmic Solution in Dry Eye in 922 participants. Completed in 14 March 2023.

Timeline

19 May 2021

Primary endpoint
14 March 2023

14 March 2023

Quick facts

Lead sponsor	Allysta Pharmaceutical
Phase	Phase 2, PHASE3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	922
Start date	19 May 2021
Primary completion	14 March 2023
Estimated completion	14 March 2023
Sites	1 location across United States

Drugs / interventions tested

ALY688 Ophthalmic Solution — full drug profile →

Conditions studied

Dry Eye — all drugs for Dry Eye →

Sponsor

Allysta Pharmaceutical — full company profile →

Who can join

18 and older, any sex, with Dry Eye. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study Evaluating the Safety and Efficacy of Two Concentrations (0.4% and 1%) of ALY688 Ophthalmic Solution in Subjects with Dry Eye Disease

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Dry eye syndrome: comprehensive etiologies and recent clinical trials.
Huang R, Su C, Fang L, Lu J, et al · · 2022 · cited 52× · PMID 35678897 · DOI 10.1007/s10792-022-02320-7
AdipoRon and Pancreatic Ductal Adenocarcinoma: a future perspective in overcoming chemotherapy-induced resistance?
Sapio L, Ragone A, Spina A, Salzillo A, et al · · 2022 · cited 5× · PMID 36176754 · DOI 10.20517/cdr.2022.34
Ocular Surface Ion Transport and Dry Eye Disease.
Lindgren ES, Cil O, Verkman AS, Pasricha ND. · · 2022 · cited 4× · PMID 38213468 · DOI 10.1007/s40135-022-00295-3
Advances and challenges of targeting epicardial adipose tissue (EAT) and perivascular adipose tissue (PVAT).
Liu D, Chen W, Guo Z, Gao Q, et al · · 2025 · cited 1× · PMID 40760703 · DOI 10.1186/s12933-025-02763-z
Unravelling the Adiponectin Hallmark and Exploring the Therapeutic Potential of Its Receptor Agonists in Cancer Metabolic Reprogramming.
Kafeel S, Palmiero G, Salzillo A, Ragone A, et al · · 2025 · PMID 40563460 · DOI 10.3390/biom15060820

Verify or expand the search:

Other recruiting trials for Dry Eye

Currently open trials in the same condition.

NCT07366944 — PCOS and Problem of Eye Dryness: Is There a Benefit From Lifetyle Changes · NA · recruiting
NCT07329712 — Comparing Tear Proteomics Profile in Dry Eye Disease pre-and Post-treatment With Low Level Light Therapy · recruiting
NCT07266948 — Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work · Phase 4 · recruiting
NCT07298811 — Preliminary Clinical Study of the Effectiveness and Safety of Ocular Surface Microbiota Transplantation in the Treatment · Phase 1, PHASE2 · recruiting
NCT07135193 — Evaluation of the Protective Effects of Cordyceps Cicadae on Visual Function and Anti-Fatigue Performance in Esports Ath · NA · active not recruiting

Other Allysta Pharmaceutical trials

Trials by the same sponsor.

NCT04855565 — ALY688-SR in Generally Healthy Overweight or Obese Adults · Phase 1 · terminated
NCT04201574 — Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease · Phase 1, PHASE2 · completed
NCT03452033 — H-1337 Ophthalmic Solution Phase 1/2 · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04899518 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Allysta Pharmaceutical
Last refreshed: 16 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04899518.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing